In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?

ABSTRACT:

Objectives

To review the main factors influencing the costs of nondaily oral preexposure prophylaxis (PrEP) with tenofovir (±emtricitabine). To estimate the cost reductions possible with nondaily PrEP compared with daily PrEP for different populations (MSM and heterosexual populations).

Design

Systematic review and data triangulation.

Methods

We estimated the required number of tablets/person/week for dosing regimens used in the HPTN 067/ADAPT (daily/time-driven/event-driven) and IPERGAY (on-demand) trials for different patterns of sexual intercourse. Using trial data, and behavioural and cost data obtained through systematic literature reviews, we estimated cost savings resulting from tablet reductions for nondaily versus daily oral PrEP, assuming 100% adherence.

SUBMITTER: Mitchell KM 

PROVIDER: S-EPMC5854532 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature